J KEVIN BUCHI
CIK 1209726 · Chief Executive Officer · last filed 2026-08-13
J KEVIN BUCHI is a Chief Executive Officer who has filed 90 SEC Form 4 insider transactions across 13 companies since 2007. The most recent filing shows the insider exercised options covering $2.9M of AMRX on Aug 13, 2026. Across all open-market trades the lifetime net is −$4.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.1M across reported positions. 7 SEC filings were submitted jointly with Ampio Pharmaceuticals, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.13M
13
90
-$4.63M
Filer Profile
FRAZER, PA 19355
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AMRX | Director | 168,576 | $17.01 | $2.87M | $0 | 12 | 2026-08-13 |
| BNTC | Director | 103,910 | $12.19 | $1.27M | $0 | 9 | 2025-12-03 |
| Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Director | 7,343 | $0.18 | $1.3K | $39.0K | 6 | 2023-06-13 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | $0 | 6 | 2021-12-29 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 4,167 | $0.87 | $3.6K | $0 | 2 | 2021-05-06 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | Chief Executive Officer | — | — | — | $0 | 1 | 2019-10-25 |
| Impax Laboratories, LLC (IPXL) Delisted | Director | 11,301 | — | — | $0 | 2 | 2017-05-17 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Director | 23,772 | — | — | $5.0K | 3 | 2015-06-25 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | — | — | — | $0 | 2 | 2015-06-08 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | President & CEO | 330,714 | — | — | $2.21M | 8 | 2015-03-30 |
| CEPHALON INC (CEPH) Delisted | Chief Executive Officer | 0 | — | — | -$6.89M | 28 | 2011-10-17 |
| ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted | Director | 0 | — | — | $0 | 7 | 2008-04-03 |
Recent Filings
90 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-13 | AMRX | Exer (M) | −168,573 | -$2.90M | EDGAR |
| 2026-08-11 | AMRX | Notice (144) | −168,573 | -$2.92M | EDGAR |
| 2026-05-08 | AMRX | Mixed | +34,819 | $0 | EDGAR |
| 2025-12-03 | BNTC | Grant (A) | — | $0 | EDGAR |
| 2025-05-08 | AMRX | Mixed | +40,258 | $0 | EDGAR |
| 2025-03-13 | BNTC | Gift (G) | — | $0 | EDGAR |
| 2025-03-12 | AMRX | Gift (G) | −262,072 | $0 | EDGAR |
| 2025-03-03 | BNTC | Exer (M) | +51,813 | $200.0K | EDGAR |
| 2024-12-11 | BNTC | Grant (A) | — | $0 | EDGAR |
| 2024-05-14 | AMRX | Exer (M) | +76,453 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.